OS Therapies Inc (OSTX) Form 10-Q — May 18, 2026
OS Therapies reported a net loss of $10.4 million for the first quarter of 2026, driven by $7.4 million in R&D expenses as it prepares regulatory submissions for its lead candidate OST-HER2. The company ended the quarter with only $917,552 in cash, leading management to disclose substantial doubt about its ability to continue as a going concern within one year. To address liquidity, OSTX completed a $4.7 million registered direct offering in April 2026, which also triggered the automatic conversion of $2.2 million in bridge notes. Earlier in the quarter, the company raised approximately $3.5 million through warrant exercise inducements and $2.0 million via a bridge financing.
Key figures
- Total Debt
- 1342942
- Cash Position
- 917552
- Shares Outstanding
- 44538106
- G and a expense q1
- 2800000
- R and d expense q1
- 7400000
- Q1 cash position 2025
- 2971007
- Operating cash flow used
- 4563538
- Stock based compensation
- 1435362
- Arbitration award accrued
- 1379361
- Bridge financing proceeds
- 2000000
- Total options outstanding
- 8357500
- Total warrants outstanding
- 11683476
- Warrant inducement proceeds
- 3500000
- Financing cash flow provided
- 5211260
- Registered direct offering proceeds
- 4700000
Price after filing
Close on the filing date to close N calendar days later (from $1.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.